HC Wainwright Issues Pessimistic Forecast for EPRX Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Stock analysts at HC Wainwright lowered their FY2030 earnings per share estimates for Eupraxia Pharmaceuticals in a research note issued to investors on Thursday, May 14th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of $0.10 for the year, down from their previous forecast of $0.17. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.85) per share.

Several other research analysts have also weighed in on EPRX. Wall Street Zen lowered Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. William Blair started coverage on Eupraxia Pharmaceuticals in a research report on Monday, March 23rd. They issued an “outperform” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Zacks Research raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Eupraxia Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Eupraxia Pharmaceuticals Trading Down 6.0%

Shares of EPRX opened at $6.29 on Monday. The company has a current ratio of 19.31, a quick ratio of 19.31 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $380.10 million, a P/E ratio of -5.99 and a beta of 1.19. The stock’s fifty day simple moving average is $7.23 and its 200 day simple moving average is $7.31. Eupraxia Pharmaceuticals has a twelve month low of $3.67 and a twelve month high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01).

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Ally Bridge Group NY LLC acquired a new position in Eupraxia Pharmaceuticals in the third quarter valued at approximately $5,398,000. Royal Bank of Canada lifted its position in Eupraxia Pharmaceuticals by 21.1% in the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after purchasing an additional 59,683 shares during the period. Goldman Sachs Group Inc. lifted its position in Eupraxia Pharmaceuticals by 44.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 58,058 shares of the company’s stock worth $438,000 after purchasing an additional 17,958 shares during the period. Quadrature Capital Ltd acquired a new stake in Eupraxia Pharmaceuticals in the fourth quarter worth approximately $326,000. Finally, Raymond James Financial Inc. lifted its stake in Eupraxia Pharmaceuticals by 173.3% during the third quarter. Raymond James Financial Inc. now owns 33,373 shares of the company’s stock valued at $197,000 after purchasing an additional 21,161 shares during the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.